The new article “Quantitative Systems Pharmacology Model That Describes Neurofilament Light Dynamics During Alzheimer's Disease Progression” by Polina Maliukova, Tatiana Karelina was published in CPT: Pharmacometrics & Systems Pharmacology Journal on June 17, 2025.

Tatiana Karelina, Head of the Neurodegenerative Diseases Modeling Group, highlights, “Neurofilament L is considered an important biomarker of degeneration and is often investigated in clinical trials related to AD, PD, MS. Its dynamics in CSF may indicate cytoskeletal degradation process. However, in AD trials, for instance, the effect on neurofilament and on another biomarker of degeneration, tau, may differ significantly. Therefore, it is difficult to estimate how the therapy slows down cytoskeletal degradation. In our study we tried to understand the mechanisms on which neurofilament secretion depends and how different types of therapy can impact neuronal cytoskeleton.

We described neurofilament dynamics in different ATN patient populations by means of assumptions and available data on intracellular processes in AD and validated the model against different therapies. It is worth mentioning that the model surely does not cover all the diversity of pathological processes but rather it is a reduced representation of groups of pathological processes. When developing the model, we tried to strike a balance between mechanistic description and clarity of the model. At the same time in the future, it can be used both in a simplified and vice versa, in a complicated detailed version, to explore new targets and their combinations."

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share